FY2025 EPS Estimates for Biohaven Cut by Leerink Partnrs

Biohaven Ltd. (NYSE:BHVN) – Equities research analysts at Leerink Partnrs dropped their FY2025 earnings per share estimates for Biohaven in a research report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates that the company will earn ($6.90) per share for the year, down from their prior forecast of ($6.05). The consensus estimate for Biohaven’s current full-year earnings is ($8.85) per share. Leerink Partnrs also issued estimates for Biohaven’s FY2027 earnings at ($3.50) EPS and FY2028 earnings at ($1.65) EPS.

Several other brokerages also recently weighed in on BHVN. Royal Bank of Canada reiterated an “outperform” rating and issued a $61.00 price target (up from $58.00) on shares of Biohaven in a report on Wednesday, December 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a report on Tuesday, December 17th. HC Wainwright reiterated a “buy” rating and issued a $59.00 target price on shares of Biohaven in a report on Tuesday, December 17th. JPMorgan Chase & Co. increased their price target on Biohaven from $55.00 to $68.00 and gave the company an “overweight” rating in a research note on Thursday, October 3rd. Finally, TD Cowen upped their target price on Biohaven from $55.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Thirteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $63.00.

Biohaven Stock Performance

Shares of BHVN opened at $38.94 on Friday. The company’s fifty day moving average is $39.80 and its 200 day moving average is $42.49. Biohaven has a fifty-two week low of $26.80 and a fifty-two week high of $62.21.

Biohaven (NYSE:BHVN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) EPS for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.03).

Institutional Investors Weigh In On Biohaven

A number of institutional investors have recently made changes to their positions in BHVN. Algert Global LLC increased its stake in Biohaven by 5.9% during the 2nd quarter. Algert Global LLC now owns 7,402 shares of the company’s stock valued at $257,000 after buying an additional 412 shares during the period. Franklin Resources Inc. lifted its position in Biohaven by 0.5% in the 3rd quarter. Franklin Resources Inc. now owns 79,705 shares of the company’s stock worth $4,206,000 after buying an additional 412 shares in the last quarter. KBC Group NV lifted its holdings in shares of Biohaven by 24.5% during the 3rd quarter. KBC Group NV now owns 2,250 shares of the company’s stock valued at $112,000 after buying an additional 443 shares during the last quarter. Hsbc Holdings PLC increased its stake in shares of Biohaven by 6.1% during the 2nd quarter. Hsbc Holdings PLC now owns 8,291 shares of the company’s stock worth $286,000 after purchasing an additional 480 shares during the last quarter. Finally, Venturi Wealth Management LLC grew its holdings in Biohaven by 19.1% during the third quarter. Venturi Wealth Management LLC now owns 3,117 shares of the company’s stock valued at $156,000 after purchasing an additional 500 shares during the last quarter. 88.78% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director John W. Childs acquired 29,000 shares of the business’s stock in a transaction on Monday, December 30th. The shares were purchased at an average price of $35.94 per share, for a total transaction of $1,042,260.00. Following the acquisition, the director now directly owns 2,368,741 shares of the company’s stock, valued at $85,132,551.54. This represents a 1.24 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 16.00% of the stock is owned by corporate insiders.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.